Acute lymphocytic leukaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acute lymphocytic leukaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces https://clinicaltrials.eu/trial/a-study-of-blinatumomab-in-children-with-relapsed-or-treatment-resistant-b-cell-acute-lymphoblastic-leukemia-with-remaining-disease-traces/ Thu, 30 Apr 2026 13:08:36 +0000 https://clinicaltrials.eu/trial/a-study-of-blinatumomab-in-children-with-relapsed-or-treatment-resistant-b-cell-acute-lymphoblastic-leukemia-with-remaining-disease-traces/ This study involves children with B-Cell Precursor Acute Lymphoblastic Leukemia, which is a type of blood cancer that affects white blood cells. The study focuses on two specific situations: when the disease has come back after treatment or has not responded to previous treatments (called relapsed or refractory), and when small amounts of cancer cells remain in the body even after treatment (called minimal residual disease positive). The treatment being tested is blinatumomab, which is given as an injection under the skin. This medication works by helping the body’s immune system find and attack cancer cells.

The purpose of the study is to test how safe and effective this under-the-skin method of giving blinatumomab is in children under 12 years of age, and to see if it can help eliminate cancer cells from the body. The study is divided into different parts. In the first part, doctors will check if the treatment is safe and well-tolerated in young children. In the second part, doctors will measure how well the treatment works by checking if cancer cells disappear from the bone marrow, which is the spongy tissue inside bones where blood cells are made.

During the study, children will receive the medication in treatment cycles, and doctors will regularly check their blood and bone marrow to see how the disease is responding. The study will also measure the levels of medication in the blood to understand how the body processes it, and will check if the body develops any reaction to the medication. Doctors will monitor for any side effects throughout the treatment period and will track how long any positive response to the treatment lasts.

]]> A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-subcutaneous-blinatumomab-in-adults-and-adolescents-with-relapsed-refractory-or-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblast/ Wed, 29 Apr 2026 15:09:46 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-subcutaneous-blinatumomab-in-adults-and-adolescents-with-relapsed-refractory-or-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblast/ This study focuses on B cell Precursor Acute Lymphoblastic Leukemia, a type of cancer that affects the blood and bone marrow. The research specifically involves individuals with Relapsed or Refractory B-ALL, which means the cancer has returned after previous treatment or has not responded to existing therapies. It also includes those with Minimal Residual Disease Positive (MRD+) B-ALL, a condition where very small amounts of cancer cells remain in the body even after treatment. The purpose of the study is to evaluate the safety and effectiveness of a new way to give the drug blinatumomab through a subcutaneous injection, which means the medicine is injected just under the skin rather than into a vein.

The study compares two different versions of the medication, referred to as SC1 and SC2. Other medications used as background treatments may include cytarabine, cyclophosphamide, dexamethasone, methotrexate, vincristine sulfate, and levetiracetam. Researchers will monitor how the body processes the medication, a process known as pharmacokinetics, and check for any side effects. The study is conducted in stages, starting with finding the right dose and then observing how well the treatment works in different groups of patients.

]]> A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers https://clinicaltrials.eu/trial/a-study-testing-the-safety-of-cd19-targeted-car-t-cell-therapy-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-cancers/ Wed, 29 Apr 2026 15:08:31 +0000 https://clinicaltrials.eu/trial/a-study-testing-the-safety-of-cd19-targeted-car-t-cell-therapy-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-cancers/ This study is looking at two types of cancer that affect certain white blood cells. The first is B-cell precursor ALL, which is a cancer where the bone marrow makes too many immature white blood cells. The second is B-cell Non Hodgkin Lymphoma, which is a cancer that starts in white blood cells called lymphocytes and can affect lymph nodes and other parts of the body. Both of these cancers have either come back after previous treatment or have not responded to treatment. The study will use a treatment called MB-huCART19.1, which is a type of therapy where a patient’s own immune cells are collected and modified in a laboratory to better recognize and attack cancer cells that have a specific marker called CD19 on their surface. These modified cells, known as CAR T-cells, are then given back to the patient through intravenous infusion, which means the cells are delivered directly into a vein.

The purpose of this study is to find out the safest dose of these modified cells that can be given to patients and to see how well the treatment works. The study will look at how many patients experience serious side effects within 28 days after receiving the treatment, which will help determine the best dose to use in the next part of the study. The study will also measure how well the treatment works by checking if the cancer responds to the treatment and how long patients remain free from disease.

During the study, patients will first have their own immune cells collected. These cells will then be modified in a laboratory to target the cancer cells. Before receiving the modified cells back, patients may receive chemotherapy to prepare their body for the treatment. After the modified cells are given through an infusion into a vein, patients will be monitored closely for side effects and to see how well the treatment is working. The study will follow patients for up to 12 months to track their progress and see if the cancer comes back. This study is for children and young adults between 1 and 45 years of age who have tried other treatments that did not work or who cannot receive other standard treatments.

]]> A study testing AZD3632 alone or with other anticancer drugs in adults with acute leukemia or myelodysplastic syndromes with HOX gene overexpression https://clinicaltrials.eu/trial/a-study-testing-azd3632-alone-or-with-other-anticancer-drugs-in-adults-with-acute-leukemia-or-myelodysplastic-syndromes-with-hox-gene-overexpression/ Wed, 29 Apr 2026 15:08:03 +0000 https://clinicaltrials.eu/trial/a-study-testing-azd3632-alone-or-with-other-anticancer-drugs-in-adults-with-acute-leukemia-or-myelodysplastic-syndromes-with-hox-gene-overexpression/ This study involves adults with certain types of blood cancers that have come back or did not respond to previous treatments. The blood cancers being studied include acute leukemia and myelodysplastic syndromes, which are conditions where the bone marrow does not produce healthy blood cells properly. These particular cancers have specific genetic changes that cause overactivity of certain genes called HOX genes. The genetic changes include mutations such as NPM1 mutation, KMT2Ar rearrangements, and several other genetic alterations. The treatment being tested is a medication called AZD3632, which is given as a tablet by mouth. In one part of the study, AZD3632 is given alone, and in another part, it is given together with posaconazole, which is another medication.

The purpose of this study is to learn how safe AZD3632 is, how well the body tolerates it, how it moves through the body over time, and whether it might help treat these blood cancers. The study is divided into different modules or parts. The first module tests AZD3632 by itself to find the best dose that is both safe and effective. This module also includes a smaller part that looks at whether eating food affects how the body absorbs the medication. The second module tests AZD3632 when given together with posaconazole to see if this combination is safe and to understand how the two medications interact in the body.

During the study, participants will take the study medication and visit the clinic regularly for check-ups. These visits will include physical examinations, blood tests to check how the body is functioning, heart monitoring tests, and assessments to see how the disease is responding to treatment. The doctors will monitor for any side effects and measure various aspects of how the medication works in the body, including the levels of medication in the blood at different times. For participants with acute leukemia, the doctors will look for signs that the cancer is responding, such as a reduction in cancer cells in the bone marrow and blood. For those with myelodysplastic syndromes, the doctors will check whether blood cell counts improve and whether participants need fewer blood transfusions. The study will also track how long any positive responses last and overall survival.

]]> Study of DDCART-CD19 cells with cyclophosphamide and fludarabine for children and young adults (up to 39 years) with recurrent acute leukemia after stem cell transplant https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ddcar-cd19-cyclophosphamide-and-fludarabine-phosphate-for-children-and-young-adults-with-relapsed-acute-leukemia/ Wed, 29 Apr 2026 15:02:00 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ddcar-cd19-cyclophosphamide-and-fludarabine-phosphate-for-children-and-young-adults-with-relapsed-acute-leukemia/ This study focuses on patients with Relapsed Acute Leukemia, a condition where blood cancer returns after previous treatment. The study tests a new treatment called DDCART-CD19, which uses specially modified immune cells (T-cells) that have been engineered to target cancer cells displaying a specific marker called CD19. This treatment is being studied in children and young adults whose leukemia has returned after receiving a stem cell transplant from a donor.

Before receiving the DDCART-CD19 cells, patients will undergo preparation treatment with cyclophosphamide and fludarabine phosphate. These medications are given through an intravenous line to help prepare the body for the cell therapy. The treatment involves collecting immune cells from the original stem cell donor, modifying them in a laboratory, and then giving them back to the patient through an intravenous infusion.

The purpose of this study is to determine how well DDCART-CD19 works and how safe it is for treating relapsed leukemia. The study will monitor patients for two years after receiving the treatment to see how their body responds and whether the leukemia stays in remission. Researchers will also track how long the modified cells remain in the patient’s blood and how they affect the disease.

]]> Study on CD19+ Lymphoid Disease Using Genetically Modified T Cells for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma https://clinicaltrials.eu/trial/study-on-cd19-lymphoid-disease-using-genetically-modified-t-cells-for-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-and-non-hodgkins-lymphoma/ Wed, 29 Apr 2026 14:59:17 +0000 https://clinicaltrials.eu/trial/study-on-cd19-lymphoid-disease-using-genetically-modified-t-cells-for-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-and-non-hodgkins-lymphoma/ This clinical trial is focused on treating patients with certain types of blood cancers, specifically Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s Lymphoma (NHL), which have either returned after treatment or have not responded to previous treatments. The study uses a special type of treatment called CD19.CAR T cells, which involves modifying a patient’s own immune cells, known as T lymphocytes, to better recognize and attack cancer cells. These modified cells are then given back to the patient through an infusion, which is a way of delivering medication directly into the bloodstream.

The purpose of the study is to evaluate the safety and feasibility of using these modified T cells in patients with these challenging blood cancers. The study will involve gradually increasing the dose of these cells to find the most effective and safe amount. Patients will receive the treatment and be monitored closely to see how their bodies respond and to check for any side effects. The study aims to understand how well the treatment works in reducing the cancer and improving patient outcomes.

Throughout the study, researchers will assess various aspects, such as the survival and function of the CAR T cells in the body, the reduction of cancer burden, and the overall response of the disease to the treatment. The study will also look at how long the response lasts and the overall survival of patients after receiving the treatment. This research is important for developing new and effective treatments for patients with these difficult-to-treat blood cancers.

]]> Study on Tisagenlecleucel for High-Risk B-Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients with Minimal Residual Disease https://clinicaltrials.eu/trial/study-on-tisagenlecleucel-for-high-risk-b-cell-acute-lymphoblastic-leukemia-in-pediatric-and-young-adult-patients-with-minimal-residual-disease/ Wed, 29 Apr 2026 14:56:40 +0000 https://clinicaltrials.eu/trial/study-on-tisagenlecleucel-for-high-risk-b-cell-acute-lymphoblastic-leukemia-in-pediatric-and-young-adult-patients-with-minimal-residual-disease/ This clinical trial is focused on studying a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL), specifically in children and young adults who are considered high-risk. The treatment being tested is called tisagenlecleucel, which is a form of cell therapy. This therapy involves using a patient’s own immune cells, which are modified to better fight cancer cells. The purpose of the study is to evaluate how effective and safe tisagenlecleucel is for patients with high-risk B-ALL who still have some cancer cells remaining after initial treatment.

Participants in the study will receive tisagenlecleucel through an infusion, which means the treatment is given directly into the bloodstream. The study will monitor patients over a period of time to see how well they respond to the treatment and to check for any side effects. The study will also compare the results of those receiving tisagenlecleucel with those who do not, to better understand the treatment’s impact on survival and disease progression.

In addition to tisagenlecleucel, the study involves other medications that are commonly used in cancer treatment, such as tocilizumab, cyclophosphamide, cytarabine, etoposide, mercaptopurine, methotrexate, vincristine sulfate, and fludarabine phosphate. These medications may be used to manage symptoms or as part of the treatment process. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatment. The study aims to provide valuable information on the potential benefits and risks of using tisagenlecleucel for treating high-risk B-ALL.

]]> Study of Inotuzumab Ozogamicin Alone and with Drug Combination for Children with Relapsed or Refractory Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-of-inotuzumab-ozogamicin-alone-and-with-drug-combination-for-children-with-relapsed-or-refractory-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:26:25 +0000 https://clinicaltrials.eu/trial/study-of-inotuzumab-ozogamicin-alone-and-with-drug-combination-for-children-with-relapsed-or-refractory-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a treatment for children with a type of blood cancer called Acute Lymphoblastic Leukemia (ALL). The study is specifically for cases where the disease has returned or has not responded to previous treatments. The treatment being tested is called Inotuzumab Ozogamicin, which is used alone or in combination with chemotherapy. The goal of the study is to find the best dose of Inotuzumab Ozogamicin for children and to see how effective it is in treating this type of leukemia.

Inotuzumab Ozogamicin is a medication that targets a specific protein found on the surface of cancer cells, known as CD22. By targeting this protein, the drug aims to destroy the cancer cells while sparing healthy cells. The study will also explore the safety and side effects of the treatment, as well as how well it works in combination with other chemotherapy drugs. The trial is divided into different parts, each focusing on different aspects of the treatment, such as its effectiveness and safety.

Participants in the study will receive the treatment over several cycles, and their response to the treatment will be closely monitored. The study aims to provide valuable information on how Inotuzumab Ozogamicin can be used to treat children with relapsed or refractory ALL, potentially leading to better treatment options in the future. The study is expected to continue until 2027, allowing researchers to gather comprehensive data on the treatment’s effectiveness and safety.

]]> Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies https://clinicaltrials.eu/trial/long-term-safety-study-of-mb-cart19-1-mb-cart20-1-and-zamtocabtagene-autoleucel-for-patients-with-advanced-melanoma-or-b-cell-malignancies/ Wed, 29 Apr 2026 14:26:06 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-mb-cart19-1-mb-cart20-1-and-zamtocabtagene-autoleucel-for-patients-with-advanced-melanoma-or-b-cell-malignancies/ This clinical trial focuses on the long-term follow-up of patients who have been treated with Miltenyi cell and gene therapies. The study involves patients with certain types of cancer, including unresectable stage III or IV melanoma, and relapsed or refractory CD19 positive B cell malignancies such as adult acute lymphoblastic leukemia (ALL), adult non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL). It also includes pediatric acute lymphoblastic leukemia and aggressive non-Hodgkin lymphoma. Additionally, the study looks at relapsed or refractory CD20 positive B-cell non-Hodgkin’s lymphoma. The treatments being studied are known as MB-CART19.1, MB-CART20.1, and MB-CART2019.1, which are types of cell therapies that use the patient’s own T cells, modified to target specific cancer cells.

The purpose of this study is to evaluate the long-term safety of these therapies. Patients who have received these treatments will be monitored over time to check for any late-onset side effects or serious health events. This includes looking for any new or returning cancers, serious infections, or other significant health issues. The study will also track the presence of certain cells in the blood, such as B and T lymphocytes, and other health indicators like height and weight in children. The presence of any remaining modified cells from the therapy will also be checked.

Participants in this study will have regular follow-up visits where their health will be assessed. This includes checking for any signs of the cancer returning or progressing and monitoring overall survival rates. The study aims to ensure that the treatments are safe in the long term and to gather important information that can help improve future therapies. The study is expected to continue until the end of 2040, providing valuable insights into the long-term effects of these innovative treatments.

]]>